Inhibition of PCSK9 with evolocumab modulates lipoproteins and monocyte activation in high-risk ASCVD subjects

CONCLUSIONS: This trial is the first to demonstrate that PCSK9 mAB with evolocumab can modulate circulating immune cell properties and highlights the importance of "stress" profiling of circulating immune cells that more clearly define immune contributions to ASCVD.PMID:38583289 | DOI:10.1016/j.atherosclerosis.2024.117529

Source: Atherosclerosis - April 7, 2024 Category: Cardiology Authors: Robert S Rosenson Ashley Tate Phyu Mar Olga Grushko Qinzhong Chen Sascha N Goonewardena Source Type: research